On Tuesday, Halozyme Therapeutics Inc (NASDAQ: HALO) opened lower -0.23% from the last session, before settling in for the closing price of $48.59. Price fluctuations for HALO have ranged from $33.15 to $65.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 41.16%. Company’s average yearly earnings per share was noted 43.80% at the time writing. With a float of $125.86 million, this company’s outstanding shares have now reached $127.18 million.
Considering the fact that the conglomerate employs 373 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 78.34%, operating margin of 50.35%, and the pretax margin is 50.68%.
Halozyme Therapeutics Inc (HALO) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Halozyme Therapeutics Inc is 1.08%, while institutional ownership is 99.34%. The most recent insider transaction that took place on Oct 15 ’24, was worth 537,469. In this transaction SVP, CHIEF TECHNICAL OFFICER of this company sold 10,000 shares at a rate of $53.75, taking the stock ownership to the 173,756 shares. Before that another transaction happened on Oct 16 ’24, when Company’s SVP, CHIEF TECHNICAL OFFICER sold 10,000 for $53.26, making the entire transaction worth $532,590. This insider now owns 173,756 shares in total.
Halozyme Therapeutics Inc (HALO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 43.80% per share during the next fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
Check out the current performance indicators for Halozyme Therapeutics Inc (HALO). In the past quarter, the stock posted a quick ratio of 9.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.51. Likewise, its price to free cash flow for the trailing twelve months is 15.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.02, a number that is poised to hit 1.17 in the next quarter and is forecasted to reach 4.60 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
Compared to the last year’s volume of 1.37 million, its volume of 1.12 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 77.51%. Additionally, its Average True Range was 2.32.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 27.51%, which indicates a significant decrease from 35.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.29% in the past 14 days, which was higher than the 52.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $53.08, while its 200-day Moving Average is $49.68. Nevertheless, the first resistance level for the watch stands at $48.94 in the near term. At $49.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $49.98. If the price goes on to break the first support level at $47.90, it is likely to go to the next support level at $47.33. Now, if the price goes above the second support level, the third support stands at $46.86.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
There are currently 127,227K shares outstanding in the company with a market cap of 6.17 billion. Presently, the company’s annual sales total 829,250 K according to its annual income of 281,590 K. Last quarter, the company’s sales amounted to 290,080 K and its income totaled 137,010 K.
